Type "best peptides" into a search engine and you get vendor best-seller lists dressed up as science journalism. So here's the version an accountability site owes you: a ranking by depth of evidence, because that's the only axis where "best" means something checkable. Compound by compound, this is how much research actually exists — and what kind. Every citation behind the lower tiers lives in our research library, where each study lists the actual experimental model it used.
Tier 1: Approved pharmaceuticals with research-grade shadows
Semaglutide and tirzepatide are the most-studied peptides on earth right now — the pharmaceutical versions passed full clinical-trial programs and carry FDA approvals for diabetes and weight management. That evidence belongs to the approved, prescribed products. The gray-market vials sold under the same names share a molecule, not a supply chain: no FDA oversight, no sterility guarantee, quality entirely dependent on the vendor — which is why batch testing is the entire game. If the medical benefit is what you want, the honest route is a prescription through a licensed telehealth provider, not a research vial.
Tier 2: Late-stage clinical candidates
Retatrutide — the triple agonist (GLP-1/GIP/glucagon) in late-stage clinical trials — is the most-hyped molecule in the research market. Real trial data exists and more is coming; it is still an unapproved investigational compound. Cagrilintide sits similarly as a clinical-stage amylin analog. Trial-stage evidence is a different thing from approval: dosing, safety margins, and long-term effects are precisely what the trials are still establishing.
Tier 3: Deep preclinical records, thin human data
This is where most famous "research peptides" actually live. BPC-157 has one of the largest preclinical files of any research peptide — decades of rodent tendon, ligament, and gut studies, now summarized by systematic reviews — and essentially no controlled human trials; the FDA has also flagged it for compounding restrictions. TB-500 (thymosin beta-4) has a similar shape: wound-healing and angiogenesis work in animal models since the late 1990s. GHK-Cu has real human data in one narrow lane — topical/cosmetic collagen studies — and mostly cell-culture work elsewhere. KPV is a genuinely interesting anti-inflammatory tripeptide whose evidence is almost entirely mouse colitis models. Interesting is not the same as established, and our research library shows the model behind every claim so you can see exactly which kind of evidence you're looking at.
Tier 4: Everything else
The long tail — epithalon, MOTS-C, SS-31, blends like GLOW — runs on early-stage papers, mechanism speculation, and marketing momentum. Some of it will graduate to real evidence; most of it won't. The tell of an honest source is that it says so.
The vendor question is separate from the molecule question
A compound with great evidence, bought from a vendor with no testing, is still a bad purchase — you don't actually know it's that compound. Evidence tiers tell you what the science supports; vendor verification tells you whether the vial matches the label. You need both, and this site exists because most places selling the first have no interest in the second.
For research use only. This article is educational and makes no health, dosing, or usage claims of any kind.